Intervention effect of Cigu Xiaozhi prescription on ceramide lipoapoptosis in non-alcoholic fatty liver disease

被引:0
作者
Yang, Shaojun [1 ]
Ma, Yanhua [2 ]
Bai, Zhouxia [3 ]
Yu, Ye [1 ]
Fang, Buwu [4 ]
Zhang, Li [4 ]
Wang, Li [2 ]
机构
[1] Beihai Tradit Chinese Med Hosp, Dept Spleen & Stomach Dis, Beihai 536000, Peoples R China
[2] Gansu Univ Tradit Chinese Med, Clin Med Coll 1, Lanzhou 730000, Peoples R China
[3] Gansu Univ Tradit Chinese Med, Affiliated Hosp, Dept Clin Lab, Lanzhou 730000, Peoples R China
[4] Tianjin Med Univ, Sch Basic Med, Dept Pharmacol, Tianjin 300070, Peoples R China
关键词
non-alcoholic fatty liver disease; ceramides; Cigu Xiaozhi prescription; detoxification and phlegm removal; SPHINGOLIPIDS; STRESS; NAFLD;
D O I
10.19852/j.cnki.jtcm.20231215.002
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
OBJECTIVE: To explore the mechanism of the Chinese medicine Cigu Xiaozhi prescription ((sic)(sic)(sic), CGXZ) in the treatment of the non-alcoholic fatty liver disease (NAFLD) by detoxification and phlegm-reducing, the effect of CGXZ prescription on ceramide-mediated lipid apoptosis in Hep G2 cells with NAFLD. METHODS: The experiment was randomly divided into 6 groups: normal control group, model group, CGXZ prescription medicated serum high, medium, and low dose groups, and pioglitazone positive control group. Using 500 mu mol/L free fatty acid (FFA) mixture to induce Hep G2 cells to establish NAFLD cell model, respectively, with 2%, 4%, and 6% concentration of CGXZ prescription medicated serum intervention for 24 h. The changes in organelles and lipid droplet accumulation were observed under the electron microscope. Furthermore, TdT-mediated dUTP Nick-End Labeling method was used to assay hepatocyte apoptosis; Biochemical determination of glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, triglycerides, and FFA levels in Hep G2 cells; the content of ceramide was determined by high- performance thin-layer chromatography. Finally, Western Blot and quantitative real-time polymerase chain reaction (qRT-PCR) were used to determine the protein and gene expression levels, such as inducible nitric oxide synthase (iNOS), nuclear factor kappa B (NF-kappa B), B cell lymphoma 2 (Bcl-2) and Bcl-2-associated X (Bax). RESULTS: Under the electron microscope, the cells in the model group showed moderate-to-severe steatosis, and apoptotic bodies could be seen. The model group had greater improvements in the apoptosis rate (P < 0.01), and the levels of ceramide C2 and FFA in the cytoplasm (P < 0.01) than the normal control group. The protein expressions of NF-kappa B, iNOS, and Bax were significantly up-regulated (P < 0.05), while the Bcl-2 had no significant change (P > 0.05). Compared with the model group, the levels of ceramide C2 and FFA (P < 0.01), the protein expressions of NF-kappa B, iNOS, and Bax (P < 0.05) in the CGXZ prescription treatment group and pioglitazone positive control group were significantly decreased; Only the Bcl-2 protein was significantly up-regulated in the high-dose Chinese medicine group (P < 0.05). The down -regulation of Bax mRNA expression in each Chinese medicine treatment group was significantly better than in the pioglitazone positive control group (P < 0.01). CONCLUSIONS: The CGXZ prescription, formulated with the method of detoxification and phlegm, can inhibit lipoapoptosis in the NAFLD cell model by down -regulating the levels of ceramide C2 and FFA, which may be achieved by regulating ceramide/iNOS/NF-kappa B signaling pathway. (c) 2024 JTCM. All rights reserved.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 24 条
  • [1] Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis
    Apostolopoulou, Maria
    Gordillo, Ruth
    Koliaki, Chrysi
    Gancheva, Sofia
    Jelenik, Tomas
    De Filippo, Elisabetta
    Herder, Christian
    Markgraf, Daniel
    Jankowiak, Frank
    Esposito, Irene
    Schlensak, Matthias
    Scherer, Philipp E.
    Roden, Michael
    [J]. DIABETES CARE, 2018, 41 (06) : 1235 - 1243
  • [2] Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters
    Cobbina, Enoch
    Akhlaghi, Fatemeh
    [J]. DRUG METABOLISM REVIEWS, 2017, 49 (02) : 197 - 211
  • [3] Ceramide channels and mitochondrial outer membrane permeability
    Colombini, Marco
    [J]. JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2017, 49 (01) : 57 - 64
  • [4] Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
    Estes, Chris
    Anstee, Quentin M.
    Teresa Arias-Loste, Maria
    Bantel, Heike
    Bellentani, Stefano
    Caballeria, Joan
    Colombo, Massimo
    Craxi, Antonio
    Crespo, Javier
    Day, Christopher P.
    Eguchi, Yuichiro
    Geier, Andreas
    Kondili, Loreta A.
    Kroy, Daniela C.
    Lazarus, Jeffrey V.
    Loomba, Rohit
    Manns, Michael P.
    Marchesini, Giulio
    Nakajima, Atsushi
    Negro, Francesco
    Petta, Salvatore
    Ratziu, Vlad
    Romero-Gomez, Manuel
    Sanyal, Arun
    Schattenberg, Joern M.
    Tacke, Frank
    Tanaka, Junko
    Trautwein, Christian
    Wei, Lai
    Zeuzem, Stefan
    Razavi, Homie
    [J]. JOURNAL OF HEPATOLOGY, 2018, 69 (04) : 896 - 904
  • [5] CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondria! Fragmentation in Obesity
    Hammerschmidt, Philipp
    Ostkotte, Daniela
    Nolte, Hendrik
    Gerl, Mathias J.
    Jais, Alexander
    Brunner, Hanna L.
    Sprenger, Hans-Georg
    Awazawa, Motoharu
    Nicholls, Hayley T.
    Turpin-Nolan, Sarah M.
    Langer, Thomas
    Krueger, Marcus
    Bruegger, Britta
    Bruening, Jens C.
    [J]. CELL, 2019, 177 (06) : 1536 - +
  • [6] Hao T, 2020, Sichuan Yi Xue Za Zhi, V41, P271
  • [7] Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
    Jiang, Meng
    Li, Chun
    Liu, Qiaoshu
    Wang, Aimin
    Lei, Minxiang
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [8] Apoptosis and non-alcoholic fatty liver diseases
    Kanda, Tatsuo
    Matsuoka, Shunichi
    Yamazaki, Motomi
    Shibata, Toshikatsu
    Nirei, Kazushige
    Takahashi, Hiroshi
    Kaneko, Tomohiro
    Fujisawa, Mariko
    Higuchi, Teruhisa
    Nakamura, Hitomi
    Matsumoto, Naoki
    Yamagami, Hiroaki
    Ogawa, Masahiro
    Imazu, Hiroo
    Kuroda, Kazumichi
    Moriyama, Mitsuhiko
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (25) : 2661 - 2672
  • [9] Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases
    Kim, Ye-Ryung
    Lee, Eun-Ji
    Shin, Kyong-Oh
    Kim, Min Hee
    Pewzner-Jung, Yael
    Lee, Yong-Moon
    Park, Joo-Won
    Futerman, Anthony H.
    Park, Woo-Jae
    [J]. EXPERIMENTAL AND MOLECULAR MEDICINE, 2019, 51 (11) : 1 - 16
  • [10] The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
    Kumar, Divya P.
    Caffrey, Rebecca
    Marioneaux, Jonathon
    Santhekadur, Prasanna K.
    Bhat, Madhavi
    Alonso, Cristina
    Koduru, Srinivas V.
    Philip, Binu
    Jain, Mukul R.
    Giri, Suresh R.
    Bedossa, Pierre
    Sanyal, Arun J.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)